A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak (Coxsackie Virus A21) [CVA 21] Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 [intercellular adhesion molecule 1] With or Without DAF [decay accelerating factor] Expressing Tumours.

Trial Profile

A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak (Coxsackie Virus A21) [CVA 21] Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 [intercellular adhesion molecule 1] With or Without DAF [decay accelerating factor] Expressing Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2017

At a glance

  • Drugs CVA 21 (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Apr 2013 Primary endpoint `patient tolerability' has been met, according to a Viralytics media release.
    • 09 Apr 2013 Results reported in a Viralytics media release.
    • 09 Nov 2012 Results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in November 2012, according to a Viralytics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top